

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Warning: To be sold by retail on the prescription of a Registered Neurologist only.

Ocrelizumab

OCREVUS®

ऑक्रेवस®

1. GENERIC NAME

Ocrelizumab 300mg Concentrate for solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredient: Ocrelizumab

OCREVUS is a clear or slightly opalescent, and colorless to pale brown solution supplied as a single-use formulation containing 300 mg Ocrelizumab.

Excipients:

Sodium Acetate Trihydrate (21.4mg) Ph.Eur./JP/USP

Glacial Acetic Acid (2.5mg) Ph.Eur./JP/ USP

α,α -Trehalose Dihydrate (400mg) Ph.Eur./JP

Polysorbate 20 (2.0mg) Ph.Eur.

Water for Injection QS 10.0 mL Ph.Eur./JP/ USP

No Preservative. The drug product is supplied at a volume of 10.0 mL in a 15 mL glass vial.

3. DOSAGE FORM AND STRENGTH

Concentrate for solution for infusion

300 mg/10 mL (30 mg/mL) clear or slightly opalescent, and colorless to pale brown solution in a single-dose vial

4. CLINICAL PARTICULARS

4.1 Therapeutic indication

OCREVUS is indicated for the treatment of:

- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
- Primary progressive MS, in adults.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

4.2 Posology and method of administration

General

Substitution by any other biological medicinal product approved in the indication requires the consent of the prescribing physician.

Premedication for infusion-related reactions

Premedicate with 100 mg IV methylprednisolone (or an equivalent) approximately 30 minutes prior to each OCREVUS infusion (see section 4.4 *Special warnings and precautions for use*) and with an antihistaminic drug (e.g. diphenhydramine) approximately 30-60 minutes before each infusion of OCREVUS to reduce the frequency and severity of infusion-related reactions.

The addition of an antipyretic (e.g. acetaminophen/paracetamol) may also be considered approximately 30-60 minutes before each infusion of OCREVUS.

Administration of OCREVUS

OCREVUS is administered as an IV infusion through a dedicated line under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious IRRs. OCREVUS infusions should not be administered as an intravenous push or bolus. Use isotonic 0.9% sodium chloride solution as the infusion vehicle. In the event an IV infusion cannot be completed the same day, the remaining liquid in the infusion bag must be discarded (see section 8.4 *Storage and handling instructions*).

Observe the patient for at least one hour after the completion of the infusion (see section 4.4. *Special Warnings and Precautions for Use*)

Initial Dose

OCREVUS is administered by IV infusion as a 600 mg dose every 6 months.

The initial 600 mg dose is administered as two separate IV infusions; first as a 300 mg infusion, followed 2 weeks later by a second 300 mg infusion.

Subsequent Doses

Subsequent doses of OCREVUS thereafter are administered as a single 600 mg IV infusion every 6 months (see Table 1).

If patients did not experience a serious infusion-related reaction (IRR) with any previous OCREVUS infusion, a shorter (2-hour) infusion can be administered for subsequent doses

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

(see Table 1, Option 2) (see sections 4.8 *Undesirable Effects, Clinical Trials* and 5.2.1 *Clinical/Efficacy Studies*)

A minimum interval of 5 months should be maintained between each dose of OCREVUS

Table 1: Dose and Schedule of OCREVUS

		Amount of OCREVUS to be administered*	
Initial Dose (600mg) divided into 2 infusions	Infusion 1	300mg in 250mL	<ul style="list-style-type: none"> • Initiate the infusion at a rate of 30 mL/hr • Thereafter, the rate can be increased in 30 mL/hr increments every 30 minutes to a maximum of 180 mL/hr. • Each infusion should be given over approximately 2.5 hr
	Infusion 2 (2 weeks later)	300mg in 250mL	
Subsequent Doses** (600 mg) single infusion once every 6 months	Option 1 Infusion of approximately 3.5 hours duration	600 mg in 500 mL	<ul style="list-style-type: none"> • Initiate the infusion at a rate of 40 mL/hr • Thereafter, the rate can be increased in 40 mL/hr increments every 30 minutes to a maximum of 200 mL/hr. • Each infusion should be given over approximately 3.5 hr
		OR	
	Option 2 Infusion of approximately 2 hours duration	600 mg in 500 mL	<ul style="list-style-type: none"> • Initiate the infusion at a rate of 100 mL/hr for the first 15 minutes • Increase the infusion rate to 200 mL/hr for the next 15 minutes • Increase the infusion rate to 250 mL/hr for the next 30 minutes • Increase the infusion rate to 300 mL/hr for the remaining 60 minutes • Each infusion should be given over approximately 2 hr

*Solutions of OCREVUS for IV infusion are prepared by dilution of the drug product into an infusion bag containing 0.9% sodium chloride, to a final drug concentration of approximately 1.2 mg/mL.

** First single infusion should be administered 6 months after Infusion 1 of Initial Dose.

Delayed or Missed Doses

If a planned infusion of OCREVUS is missed, it should be administered as soon as possible; do not wait until the next planned dose. The treatment interval for OCREVUS should be maintained between doses.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Infusion Adjustments during Treatment:

No dose reductions of OCREVUS are recommended.

In case of infusion-related reactions (IRRs) during any infusion, see the following adjustments. Additional information on IRRs can be found in section 4.4.4 *Special warnings and precautions for use, General, Infusion-Related Reactions*.

Life-threatening IRRs

Immediately stop OCREVUS if there are signs of a life-threatening or disabling infusion-related reaction during an infusion, such as acute hypersensitivity or acute respiratory distress syndrome. The patient should receive appropriate supportive treatment. Permanently discontinue OCREVUS in these patients.

Severe IRRs

If a patient experiences a severe infusion-related reaction or a complex of flushing, fever, and throat pain symptoms, the infusion should be interrupted immediately and the patient should receive symptomatic treatment. The infusion should be restarted only after all symptoms have resolved. The initial infusion rate at restart should be half of the infusion rate at the time of onset of the reaction.

Mild to Moderate IRRs

If a patient experiences a mild to moderate infusion-related reaction (e.g. headache), the infusion rate should be reduced to half the rate at the onset of the event. This reduced rate should be maintained for at least 30 minutes. If tolerated, the infusion rate may then be increased according to the patient's initial infusion schedule.

See section 4.4 *Special warnings and precautions for use, General, Infusion-Related Reactions* for full description of symptoms associated with IRRs.

4.3 Contraindications

OCREVUS is contraindicated in patients with a known hypersensitivity to Ocrelizumab or to any of the excipients.

4.4 Special warnings and precautions for use

General

In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded (or stated) in the patient file.

Infusion-Related Reactions (IRRs)

OCREVUS is associated with IRRs, which may be related to cytokine release and/or other chemical mediators.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Symptoms of IRRs may occur during any infusion, but have been more frequently reported during the first infusion. IRRs can occur within 24 hours of the infusion (see section 4.8 *Undesirable Effects*). These reactions may present as pruritus, rash, urticaria, erythema, throat irritation, oropharyngeal pain, dyspnoea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, and tachycardia, and anaphylaxis (see section 4.8 *Undesirable Effects*). Patients treated with OCREVUS should be observed for at least one hour after the completion of the infusion for any symptom of IRR. Physicians should alert patients that IRRs can occur within 24 hours of infusion.

A hypersensitivity reaction could also occur (acute allergic reaction to drug). IRRs may be clinically indistinguishable from type 1 (IgE-mediated) acute hypersensitivity reactions (see *Hypersensitivity Reactions*).

For premedication to reduce the frequency and severity of IRRs see section 4.2 *Posology and method of administration*

Managing infusion-related reactions:

For patients experiencing life threatening, severe or mild to moderate IRR symptoms see section 4.2 *Posology and method of administration, Infusion Adjustments during Treatment*.

Patients who experience severe pulmonary symptoms, such as bronchospasm or asthma exacerbation, must have their infusion interrupted immediately and permanently. After administering symptomatic treatment, monitor the patient until the pulmonary symptoms have resolved because initial improvement of clinical symptoms could be followed by deterioration.

Hypotension, as a symptom of IRR, may occur during OCREVUS infusions. Therefore, withholding of antihypertensive treatments should be considered for 12 hours prior to and throughout each OCREVUS infusion. Patients with a history of congestive heart failure (New York Heart Association III & IV) were not studied.

Hypersensitivity Reactions

No hypersensitivity reactions to OCREVUS were reported in the controlled clinical trials.

Hypersensitivity may be difficult to distinguish from IRRs in terms of symptoms. A hypersensitivity reaction may present during any infusion, although typically would not present during the first infusion. For subsequent infusions, more severe symptoms than previously experienced, or new severe symptoms, should prompt consideration of a potential hypersensitivity reaction. If a hypersensitivity reaction is suspected during infusion, the infusion must be stopped immediately and permanently. Patients with known IgE-mediated hypersensitivity to Ocrelizumab must not be treated (see section 4.3 *Contraindications*).

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Infections

Delay OCREVUS administration in patients with an active infection until the infection is resolved.

Progressive multifocal leukoencephalopathy (PML)

John Cunningham (JC) virus infection resulting in PML has been observed in patients treated with anti-CD20 antibodies, including OCREVUS, and mostly associated with risk factors (e.g. patient population, polytherapy with immunosuppressants). The reporting rate with OCREVUS has been approximately 1 case per 100,000 patients.

Since a risk of PML cannot be ruled out, physicians should be vigilant for early signs and symptoms of PML, which can include any new onset, or worsening of neurological signs or symptoms as these can be similar to an MS relapse.

If PML is suspected, withhold dosing with OCREVUS. Evaluation of PML, including MRI scan preferably with contrast (compared with pre-treatment MRI), confirmatory CSF testing for JC Viral DNA and repeat neurological assessments, should be considered.

If PML is confirmed, discontinue treatment permanently.

Hepatitis B reactivation

Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, has been reported in patients treated with anti-CD20 antibodies.

HBV screening should be performed in all patients before initiation of treatment with OCREVUS as per local guidelines. Patients with active Hepatitis B virus (HBV), (i.e. an active infection confirmed by positive results for HBsAg and anti HB testing) should not be treated with OCREVUS. Patients with positive serology (i.e. negative for HBsAg and positive for HB core antibody [HBcAb+]; carriers of HBV [positive for surface antigen, HBsAg+]) should consult liver disease experts before start of treatment and should be monitored and managed following local medical standards to prevent hepatitis B reactivation.

Treatment with immunosuppressants before, during or after OCREVUS

When initiating OCREVUS after an immunosuppressive therapy or initiating an immunosuppressive therapy after OCREVUS, the potential for overlapping pharmacodynamics effects should be taken into consideration (see section 5.1 *Mechanism of Action*, & 5.2 *Pharmacodynamic effects*). Exercise caution when prescribing OCREVUS taking into consideration the pharmacodynamics of other disease modifying MS therapies. OCREVUS has not been studied in combination with other disease modifying MS therapies.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Vaccinations

The safety of immunization with live or live-attenuated vaccines, following OCREVUS therapy has not been studied and vaccination with live-attenuated or live vaccines is not recommended during treatment and until B-cell repletion (see section 5.1 *Mechanism of Action*, & 5.2 *Pharmacodynamic effects*)

After treatment with OCREVUS over 2 years, the proportion of patients with positive antibody titers against *S. pneumoniae*, mumps, rubella, varicella were generally similar to the proportions at baseline.

In a randomized open-label study, RMS patients treated with OCREVUS were able to mount humoral responses, albeit decreased, to tetanus toxoid, 23-valent pneumococcal polysaccharide, keyhole limpet hemocyanin neoantigen, and seasonal influenza vaccines. It is still recommended to vaccinate patients treated with OCREVUS with seasonal influenza vaccines that are inactivated

Physicians should review the immunization status of patients before starting treatment with OCREVUS. Patients who require vaccination should complete their immunizations at least 6 weeks prior to initiation of OCREVUS.

Exposure in utero to Ocrelizumab and vaccination of neonates and infants with live or live-attenuated vaccines

Due to the potential depletion of B-cells in neonates and infants of mothers who have been exposed to OCREVUS during pregnancy, it is recommended that vaccination with live or live-attenuated vaccines should be delayed until B-cell levels have recovered; therefore, measuring CD19-positive B-cell level, in neonates and infants, prior to vaccination is recommended.

It is recommended that all vaccinations other than live or live-attenuated should follow the local immunization schedule and measurement of vaccine-induced response titers should be considered to check whether individuals can mount a protective immune response because the efficacy of the vaccination may be decreased.

4.5 Drugs interactions

No formal drug interaction studies have been performed, as no drug interactions are expected via the CYP and other metabolizing enzymes or transporters

4.6 Use in special populations (such as pregnant women, lactating women, paediatric patients, geriatric patients etc.)

4.6.1 Females and Males of Reproductive Potential

Fertility

No text (see section 6.1.3 *Impairment of Fertility*).

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Contraception

Women of childbearing potential should use contraception while receiving OCREVUS and for 6 months after the last infusion of OCREVUS (see section 5.3 *Pharmacokinetic Properties, Elimination*).

4.6.2 Pregnancy

OCREVUS is a humanized monoclonal antibody of an immunoglobulin G1 subtype and immunoglobulins are known to cross the placental barrier.

OCREVUS should be avoided during pregnancy unless the potential benefit to the mother outweighs the potential risk to the fetus. There are no adequate and well-controlled data from studies in pregnant women; however, transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 antibodies during pregnancy (see section 6 *Nonclinical Properties, Reproductive Toxicity*)

Reproductive Toxicity

Postponing vaccination with live or live-attenuated vaccines should be considered for neonates and infants born to mothers who have been exposed to OCREVUS in utero B-cell levels in neonates and infants following maternal exposure to OCREVUS have not been studied in clinical trials and the potential duration of B-cell depletion in neonates Females and Males of Reproductive Potential and infants is unknown (see section 4.4 *Special warnings and precautions for use, General, Vaccinations*).

Labor and Delivery

The safe use of OCREVUS during labor and delivery has not been established.

4.6.3 Lactation

It is unknown whether OCREVUS is excreted in human breast milk or has any effect on the breastfed child and on milk production. Animal studies have shown excretion of Ocrelizumab in breast milk (see section 6 *Nonclinical Properties, Reproductive Toxicity*). Because human IgG is excreted in human milk, and the potential for Ocrelizumab absorption leading to B-cell depletion is unknown, women should be advised to discontinue breastfeeding during OCREVUS therapy.

4.6.4 Pediatric Use

The safety and efficacy of OCREVUS in children and adolescents (<18 years of age) has not been studied.

4.6.5 Geriatric Use

The safety and efficacy of OCREVUS in patients ≥ 65 years of age has not been studied.

4.6.6 Renal Impairment

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

The safety and efficacy of OCREVUS in patients with renal impairment has not been formally studied. Patients with mild renal impairment were included in clinical trials. OCREVUS is a monoclonal antibody and cleared via catabolism (rather than renal excretion), and a change in dose is not expected to be required for patients with renal impairment (see section 3.2.5 *Pharmacokinetics in Special Populations, Renal Impairment*).

4.6.7 Hepatic Impairment

The safety and efficacy of OCREVUS in patients with hepatic impairment has not been formally studied. Patients with mild hepatic impairment were included in clinical trials. OCREVUS is a monoclonal antibody and cleared via catabolism (rather than hepatic metabolism), and a change in dose is not expected to be required for patients with hepatic impairment (see section 5.3 *Pharmacokinetics in Special Populations, Hepatic Impairment*).

4.7 Effects on ability to drive and use machines

OCREVUS has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Clinical Trials

The safety of OCREVUS has been evaluated in 1311 patients across MS clinical studies, which includes 825 patients in active-controlled (RMS) clinical trials and 486 patients in a placebo-controlled (PPMS) study. Table 2 summarizes the adverse drug reactions (ADRs) that have been reported in association with the use of OCREVUS in clinical trials. The most frequently reported ADRs were IRRs and respiratory tract infections

Relapsing forms of MS

The ADRs described in this section were identified based on data from two identical active-controlled studies WA21092 and WA21093 to evaluate the efficacy and safety of OCREVUS in adults with relapsing forms of MS (RMS). In the two studies, patients were given OCREVUS 600 mg (n=825), every 6 months (with the first dose administered as two 300 mg IV infusions separated by 2 weeks and all subsequent doses as a single, 600 mg infusion), or interferon beta-1a (IFN) 44 mcg (n=826) subcutaneous 3 times per week. The controlled period of the study was 96 weeks (4 doses of OCREVUS).

Primary Progressive MS

The ADRs described in this section were identified based on data from a placebo-controlled study WA25046 to evaluate the efficacy and safety of OCREVUS in adults with primary progressive MS (PPMS). Patients were given OCREVUS 600 mg (n=486) or placebo (n=239)

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

every 6 months (administered as two 300 mg infusions separated by 2 weeks during the entire study).

Frequencies are defined as very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$) and very rare ($< 1/10,000$). Adverse reactions are presented in order of decreasing frequency.

Table 2 Summary of ADRs associated with OCREVUS (in RMS or PPMS) with an incidence of $\geq 2\%$ and higher than the comparator¹

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

ADR (MedDRA)	RMS Pooled WA21092 & WA21093		PPMS WA25046 ²		Frequency category for OCREVUS
	OCREVU S n=825	Interferon beta-1a n=826	OCREVUS n=486	Placebo n=239	
Injury, Poisoning and Procedural Complications					
Infusion-related Reaction ³	283 (34.3%)	82 (9.9%)	195 (40.1%)	61 (25.5%)	Very common
Infections and infestations					
Upper respiratory tract infection	125 (15.2%)	88 (10.7%)	59 (12.1%)	14 (5.9%)	Very common
Nasopharyngitis	123 (14.9%)	84 (10.2%)	117 (24.1%)	67 (28.0%)	Very common
Sinusitis	46 (5.6%)	45 (5.4%)	19 (3.9%)	7 (2.9%)	Common
Bronchitis	42 (5.1%)	29 (3.5%)	31 (6.4%)	15 (6.3%)	Common
Influenza	38 (4.6%)	39 (4.7%)	57 (11.7%)	20 (8.4%)	Very common
Gastroenteritis	25 (3.0%)	19 (2.3%)	22 (4.5%)	12 (5.0%)	Common
Oral herpes	25 (3.0%)	18 (2.2%)	13 (2.7%)	2 (0.8%)	Common
Respiratory tract infection	19 (2.3%)	17 (2.1%)	13 (2.7%)	2 (0.8%)	Common
Viral infection	18 (2.2%)	23 (2.8%)	15 (3.1%)	4 (1.7%)	Common
Herpes zoster	17 (2.1%)	8 (1.0%)	8 (1.6%)	4 (1.7%)	Common
Conjunctivitis	9 (1.1%)	5 (0.6%)	10 (2.1%)	1 (0.4%)	Common
Cellulitis	7 (0.8%)	5 (0.6%)	11 (2.3%)	1 (0.4%)	Common
Respiratory, thoracic and mediastinal disorders					
Cough	25 (3.0%)	12 (1.5%)	34 (7.0%)	8 (3.3%)	Common
Catarrh	0	0	10 (2.1%)	2 (0.8%)	Common

¹Interferon beta-1a 44 mcg s.c. or Placebo

²PPMS patients were randomized 2:1 (OCREVUS: placebo).

³Symptoms reported as IRRs within 24 hours of infusion are described below in "Infusion-related reactions"

Infusion-related reactions

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Across the RMS and PPMS trials, symptoms associated with IRRs included, but are not limited to: pruritus, rash, urticaria, erythema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, throat irritation, oropharyngeal pain, dyspnoea, pharyngeal or laryngeal edema, nausea, and tachycardia. In the controlled clinical trials there were no fatal IRRs.

In active-controlled (RMS) clinical trials, IRRs were the most common adverse event in patients treated with OCREVUS 600 mg with an overall incidence of 34.3% compared with an incidence of 9.9% in the interferon beta-1a treatment group (placebo infusion). The incidence of IRRs was highest during Dose 1, infusion 1 (27.5%) and decreased over time to <10% at Dose 4. The majority of IRRs in both treatment groups were mild to moderate (see section 4.4 *Special warnings and precautions for use, General, Infusion- Related Reactions*).

In the placebo-controlled (PPMS) clinical trial, the incidence of IRRs was highest during Dose 1, infusion 1 (27.4%) and decreased with subsequent Doses to <10% at Dose 4. A greater proportion of patients in each group experienced IRRs with the first infusion of each dose compared with the second infusion of that dose. The majority of IRRs were mild to moderate (see section 4.4 *Special warnings and precautions for use, General, Infusion- Related Reactions*).

Alternative Shorter Infusion of Subsequent Doses

In a study (MA30143 Shorter Infusion Sub study) designed to characterize the safety profile of shorter (2-hour) OCREVUS infusions in patients with Relapsing-Remitting Multiple Sclerosis, the incidence, intensity, and types of symptoms of IRRs were consistent with those of infusions administered over 3.5 hours (see section 5.2.1 *Clinical/Efficacy Studies*).

Infection

There was no increase in serious infections associated with OCREVUS treatment (in RMS patients the rate of serious infections was lower than for interferon beta-1a, and in PPMS patients the rate was similar to placebo).

In the active-controlled (RMS) and the placebo-controlled (PPMS) clinical trials, respiratory tract infections and herpes infections (both predominantly mild to moderate) were more frequently reported in the OCREVUS treatment arm.

Respiratory Tract Infections

The proportion of respiratory tract infections was higher in the OCREVUS treated patients compared to interferon and placebo. The infections were predominately mild to moderate and consisted mostly of upper respiratory tract infections (including nasopharyngitis) and bronchitis (see Table 2).

Herpes

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

In active-controlled (RMS) clinical trials, herpes infections were reported more frequently in OCREVUS-treated patients than interferon beta-1a treated patients including herpes zoster (2.1% vs 1.0%), herpes simplex, (0.7% vs 0.1%) and oral herpes (3.0% vs 2.2%), genital herpes (0.1% vs 0%), herpes virus infection (0.1% vs 0%). Infections were predominantly mild to moderate in severity and patients recovered with treatment by standard therapies. There were no reports of disseminated herpes.

In the placebo-controlled (PPMS) clinical trial, a higher proportion of patients with oral herpes (2.7% vs 0.8%) were observed in the OCREVUS treatment arm.

OCREVUS in combination with concomitant immunosuppressive medications (e.g. chronic steroids, non-biologic and biologic disease-modifying antirheumatic drugs [DMARDs], mycophenolate mofetil, cyclophosphamide, azathioprine) has been studied in other autoimmune conditions.

The majority of available data is from studies in patients with rheumatoid arthritis (RA), where an imbalance in serious infections was observed, including, but not limited to, atypical pneumonia and pneumocystis jirovecii pneumonia, varicella pneumonia, tuberculosis, histoplasmosis in the OCREVUS-immunosuppressant group. In rare cases, some of these infections were fatal. Serious infections were reported more frequently in the 1000 mg dose group compared to the 400 mg dose group or immunosuppressant- placebo group.

Risk factors for serious infections in these trials included other comorbidities, chronic use of immunosuppressants/steroids, and patients from Asia.

Laboratory Abnormalities

Immunoglobulins

Treatment with OCREVUS resulted in a decrease in total immunoglobulins over the controlled period of the studies, mainly driven by reduction in IgM.

In the active-controlled (RMS) studies, the proportion of patients, at baseline, reporting IgG, IgA and IgM < lower limit of normal (LLN) in the OCREVUS treatment arm was 0.5%, 1.5% and 0.1% respectively. Following treatment, the proportion of OCREVUS-treated patients reporting IgG, IgA and IgM < LLN at 96 weeks was 1.5%, 2.4% and 16.5% respectively.

In the placebo-controlled (PPMS) study, the proportion of patients, at baseline, reporting IgG, IgA and IgM < LLN in the OCREVUS treatment arm was 0.0%, 0.2% and 0.2% respectively. Following treatment, the proportion of OCREVUS-treated patients reporting IgG, IgA and IgM < LLN at 120 weeks was 1.1%, 0.5% and 15.5% respectively.

The pooled data of the OCREVUS pivotal clinical studies (RMS and PPMS) and their open-label extensions (up to approximately 7 years of exposure) have shown an apparent association

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

between decreased levels of immunoglobulins and serious infections (SI), and was most apparent for IgG (0.5% of patients had a SI during a period with IgG < LLN). The type, severity, latency, duration, and outcome of SIs observed during episodes of immunoglobulins below LLN were consistent with the overall SIs observed in patients treated with OCR.

Neutrophils

In the active-controlled (RMS) treatment period, decreased neutrophils were observed in 14.7% of OCREVUS patients as compared to 40.9% of patients treated with interferon beta-1a. In the placebo-controlled (PPMS) clinical trial, the proportion of OCREVUS patients presenting decreased neutrophils was slightly higher (12.9%) than placebo patients (10.0%).

The majority of the decreased neutrophils were transient (only observed once for a given patient treated with OCREVUS) and were Grade 1 and 2 in severity.

Overall, approximately 1% of the patients in the OCREVUS group had Grade 3 or 4 neutropenia and was not temporally associated with an infection.

4.9 Overdose

There is limited clinical trial experience with doses higher than the approved intravenous dose of OCREVUS. The highest dose tested to date in MS patients is 2000 mg, administered as two 1000 mg IV infusions separated by 2 weeks (Phase II dose finding study in RRMS). The adverse drug reactions were consistent with the safety profile for OCREVUS in the pivotal clinical studies.

There is no specific antidote in the event of an overdose; interrupt the infusion immediately and observe the patient for infusion-related reactions (*see section 4.4 Special warnings and precautions for use, General, Infusion- Related Reactions*)

5. PHARMACOLOGICAL PROPERTIES

5.1 Mechanism of Action

Ocrelizumab is a recombinant humanized monoclonal antibody that selectively targets CD20-expressing B-cells.

CD20 is a cell surface antigen found on pre-B-cells, mature and memory B-cells but not expressed on lymphoid stem cells and plasma cells.

The precise mechanisms through which Ocrelizumab exerts its therapeutic clinical effects in MS are not fully elucidated but is presumed to involve immunomodulation through the reduction in the number and function of CD20-expressing B-cells. Following cell surface binding, Ocrelizumab selectively depletes CD20-expressing B-cells through antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), complement-dependent

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

cytotoxicity (CDC), and apoptosis. The capacity of B-cell reconstitution and preexisting humoral immunity are preserved.

In addition, innate immunity and total T-cell numbers are not affected.

5.2 Pharmacodynamic properties

Treatment with OCREVUS leads to rapid depletion of CD19+ B-cells in blood by 14 days post treatment (first time-point of assessment) as an expected pharmacologic effect. This was sustained throughout the treatment period. For the B-cell counts, CD19 is used as the presence of OCREVUS interferes with the recognition of CD20 by the assay (see section 5.1 *Mechanism of Action*).

In the Phase III studies, between each dose of OCREVUS, up to 5% of patients showed B-cell repletion (> lower limit of normal (LLN) or baseline) at least at one time point. The extent and duration of B-cell depletion was consistent in the PPMS and RMS trials.

The longest follow up time after the last OCREVUS infusion (Phase II WA21493, N=51) indicates that the median time to B-cell repletion (returned to baseline/LLN whichever occurred first) was 72 weeks (range 27 - 175 weeks). Ninety percent of all patients had their B-cells repleted to LLN or baseline by approximately two and a half years after the last infusion

5.2.1 Clinical / Efficacy Studies

Relapsing forms of MS

Efficacy and safety of OCREVUS were evaluated in two randomized, double-blind, double-dummy, active comparator-controlled clinical trials with identical design, in patients with relapsing forms of MS (in accordance with McDonald criteria 2010). Study design and baseline characteristics of the study population are summarized in Table 3.

Demographic and baseline characteristics were well balanced across the two treatment groups. Patients receiving OCREVUS (Group A) were given 600mg every 6 months (Dose 1 as 2 x 300 mg IV infusions, administered 2 weeks apart), and subsequent doses were administered as a single 600 mg IV infusion. Patients in Group B were administered Interferon beta-1a (Rebif®) 44 mcg via subcutaneous (s.c.) injection 3 times per week.

Key clinical and MRI efficacy results are presented in Table 4 and Figure 1.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Table 3 Study Design and Demographic Characteristics

	Study 1		Study 2	
Study name	WA21092 (OPERA I)		WA21093 (OPERA II)	
	Study design			
Study population	Patients with relapsing forms of MS			
Disease history at screening	At least two relapses within the prior two years or one relapse within the prior year; EDSS between 0 and 5.5, inclusive			
Study duration	2 years (96 weeks)			
Treatment groups	Group A: OCREVUS 600 mg Group B: interferon beta-1A (Rebif®), 44 mcg s.c. (IFN)			
Baseline characteristics	OCREVUS 600 mg (n=410)	IFN 44 mcg (n=411)	OCREVUS 600 mg (n=417)	IFN 44 mcg (n=418)
Mean age (years)	37.1	36.9	37.2	37.4
Gender distribution (% male/% female)	34.1/65.9	33.8/66.2	35.0/65.0	33.0/67.0
Mean/Median duration since onset of MS symptoms (years)	6.74/4.88	6.25/4.62	6.72/5.16	6.68/5.07
Mean/Median disease duration since diagnosis (years)	3.82/1.53	3.71/1.57	4.15/2.10	4.13/1.84
Mean number of relapses in the last year	1.31	1.33	1.32	1.34
Mean Gd-enhancing T1 Lesion count	1.69	1.87	1.82	1.95
Mean T2 lesion count	51.04	51.06	49.26	51.01

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Table 4 Key Clinical and MRI Endpoints from Studies WA21092 and WA21093

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Endpoints	Study 1: WA21092 (OPERA I)		Study 2: WA21093 (OPERA II)	
	OCREVUS 600 mg (n=410)	IFN 44 mcg (n=411)	OCREVUS 600 mg (n=417)	IFN 44 mcg (n=418)
Clinical Endpoints				
Annualized Relapse Rate (primary endpoint)	0.156	0.292	0.155	0.290
Relative Reduction	46% (p<0.0001)		47% (p<0.0001)	
Proportion of patients with 12-week Confirmed Disability Progression ³	9.8% OCREVUS vs 15.2% IFN			
Risk Reduction (Pooled Analysis ¹)	40% (p=0.0006)			
Risk Reduction (Individual Studies ²)	43% (p=0.0139)		37% (p=0.0169)	
Proportion of patients with 24-week Confirmed Disability Progression ³	7.6% OCREVUS vs 12.0% IFN			
Risk Reduction (Pooled Analysis ¹)	40% (p=0.0025)			
Risk Reduction (Individual Studies ²)	43% (p=0.0278)		37% (p=0.0370)	
Proportion of patients with at least 12-weeks Confirmed Disability Improvement ⁴ (Pooled)	20.7% OCREVUS vs 15.6% IFN			
Relative Increase (Pooled Analysis ¹)	33% (p=0.0194)			
Relative Increase (Individual Studies ²)	61% (p=0.0106)		14% (p=0.4019)	
Mean change from baseline in Multiple Sclerosis Functional Composite (MSFC)	0.213	0.174	0.276	0.169
Difference	0.039 (p= 0.3261)		0.107 (p=0.0040)	
Proportion of patients with No Evidence of Disease	48%	29%	48%	25%
Relative Increase ²	64% (p<0.0001)		89% (p<0.0001)	
MRI Endpoints				
Mean number of T1 Gd-enhancing lesions per MRI scan	0.016	0.286	0.021	0.416
Relative reduction	94% (p<0.0001)		95% (p<0.0001)	
Mean number of new and/or enlarging T2 hyperintense lesions per MRI scan	0.323	1.413	0.325	1.904
Relative reduction	77% (p<0.0001)		83% (p<0.0001)	
Mean number of new T1-hypo-intense lesions (chronic blackholes) per MRI scan	0.420	0.982	0.449	1.255
Relative reduction	57% (p<0.0001)		64% (p<0.0001)	
Percentage change in brain volume from Week 24 to week 96	-0.572	-0.741	-0.638	-0.750
Relative reduction in brain volume loss	22.8% (p=0.0042) ⁶		14.9% (p=0.0900)	
Quality of Life				
Mean change from baseline in SF-36 Physical Component Summary				
Difference	0.036	-0.657	0.326	-0.833
	0.693 (p=0.2193)		1.159 (p=0.0404) ⁸	

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

¹Data prospectively pooled from Study 1 & 2

²Non-confirmatory p-value; analysis not part of the pre-specified testing hierarchy


³Defined as an increase of ≥ 1.0 point from the baseline Expanded Disability Status Scale (EDSS) score for patients with baseline score of 5.5 or less, or ≥ 0.5 when the baseline score is > 5.5 , Kaplan-Meier estimates at Week 96

⁴Defined as decrease of ≥ 1.0 point from the baseline EDSS score for patients with baseline EDSS score ≥ 2 and ≤ 5.5 , or ≥ 0.5 when the baseline score is > 5.5 . Patients with baseline score < 2 were not included in analysis.

⁵NEDA defined as absence of protocol defined relapses, Confirmed Disability Progression (CDP), and any MRI activity (either Gd-enhancing T1 lesions, or new or enlarging T2 lesions) during the whole 96-week treatment. Exploratory result based on complete ITT population.

⁶Non-confirmatory p-value; hierarchical testing procedure terminated before reaching endpoint

Figure 1: Kaplan-Meier Plot of Time to Onset of Confirmed Disability Progression Sustained for at Least 12 Weeks with the Initial Event of Neurological Worsening Occurring during the Double-blind Treatment Period (Pooled ITT Population)*



*Pre-specified pooled analysis of OPERA I & II

Results of the pre-specified pooled analyses of time to CDP sustained for at least 12 weeks (40% risk reduction for OCREVUS compared to interferon beta-1a, $p=0.0006$) were highly consistent with the results sustained for at least 24 weeks (40% risk reduction for OCREVUS compared to interferon beta-1a, $p=0.0025$).

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Shorter Infusion Substudy

The safety of the shorter (2-hour) OCREVUS infusion was evaluated in a prospective, multicenter, randomized, double-blind, controlled, parallel arm substudy to Study MA30143 (Ensemble) in patients with Relapsing-Remitting Multiple Sclerosis that were naïve to other disease modifying treatments. The first dose of OCREVUS was administered as two 300 mg infusions (600 mg total) separated by 14 days. Patients were randomized from their second dose or onwards (Dose 2 to 6) in a 1:1 ratio to either the conventional infusion group with OCREVUS infused over approximately 3.5 hours every 24 weeks, or the shorter infusion group with OCREVUS infused over approximately 2 hours every 24 weeks. The randomization was stratified by region and the dose at which patients were first randomized.

The primary endpoint was the proportion of patients with IRRs occurring during or within 24 hours following the first randomized infusion of OCREVUS. The primary analysis was performed when 580 patients were randomized. The proportion of patients with IRRs occurring during or within 24 hours following the first randomized infusion was 24.6% in the shorter infusion group compared to 23.1% in the conventional infusion group. The stratified group difference was similar. Overall, in all randomized doses, the majority of the IRRs were mild or moderate and only two IRRs were severe in intensity, with one severe IRR in each group. There were no life-threatening, fatal, or serious IRRs.

Primary Progressive MS

Efficacy and safety of OCREVUS were also evaluated in a randomized, double-blind, placebo-controlled clinical trial in patients with primary progressive MS (Study WA25046). Study design and baseline characteristics of the study population are presented in Table 5.

Demographic and baseline characteristics were well balanced across the two treatment groups.

Patients receiving OCREVUS (Group A) were given 600 mg every 6 months (as 2 x 300 mg IV infusions, administered 2 weeks apart. Patients in Group B were administered placebo. During the Phase 3 PPMS study, patients received the 600 mg dose as two 300 mg infusions, given two weeks apart throughout the treatment period. The 600 mg infusions in RMS and the 2 x 300 mg infusions in PPMS demonstrated consistent PK/PD profiles. IRR profiles per infusion are also similar, independent of whether the 600 mg dose was administered as a single 600 mg infusion or as two 300 mg infusions separated by two weeks (see sections 4.8 *Undesirable Effects* and 5.3 *Pharmacokinetic Properties*), but due to overall more infusions with the 2 x 300 mg regimen, the total number of IRRs are higher. Therefore, after Dose 1 it is recommended to administer OCREVUS in a 600 mg single infusion (see Table 1) to reduce the total number of infusions, (with concurrent exposure to prophylactic methylprednisolone) and the related infusion reactions

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Table 5 Study design and baseline characteristics for Study WA25046

Study Name	Study WA25046 ORATORIO (n=732)	
	Study design	
Study population	Patients with primary progressive form of MS	
Study duration	Event-driven (<i>Minimum 120 weeks and 253 confirmed disability progression events</i>) <i>Median follow-up time: OCREVUS 3.0 years, Placebo 2.8 years</i>	
Disease history at screening	Age 18-55 years, EDSS of 3.0 to 6.5	
Treatment groups	Group A: OCREVUS 600 mg Group B: Placebo, in 2:1 randomization	
Baseline characteristics	OCREVUS 600 mg (n=488)	Placebo (n=244)
Mean Age (years)	44.7	44.4
Gender distribution (% male/% female)	51.4/48.6	49.2/50.8
Mean/Median duration since onset of MS symptoms (years)	6.7/6.0	6.1/5.5
Mean/Median disease duration since PPMS diagnosis (years)	2.9/1.6	2.8/1.3
Mean EDSS	4.7	4.7

Key clinical and MRI efficacy results are presented in Table 6 and Figure 2

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory


Table 6 Key Clinical and MRI Endpoints from Study WA25046 (PPMS)

		Study 3	
Endpoints		WA25046 (Oratorio)	
		OCREVUS 600 mg (n=488)	Placebo (n=244)
Clinical Endpoints			
Primary efficacy endpoint Proportion of patients with 12 weeks - Confirmed Disability Progression ¹ (primary endpoint) Risk reduction		30.2%	34.0%
		24% (p=0.032)	
Proportion of patients with 24 weeks - Confirmed Disability Progression ¹ Risk reduction		28.3%	32.7%
		25% (p=0.0365)	
Percentage change in Timed 25-Foot Walk from baseline to Week 120 Relative reduction in progression rate of walking time		38.9	55.1
		29.4% (p=0.0404)	
MRI Endpoints			
Percentage change in T2 hyperintense lesion volume, from baseline to Week 120		-3.4	7.4
		(p< 0.0001)	
Percentage change in brain volume from Week 24 to Week 120 Relative reduction in rate of brain volume loss		-0.902	-1.093
		17.5% (p=0.0206)	
Quality of Life			
Mean change from baseline in SF-36 Physical Component Summary Difference		-0.731	-1.108
		0.377 (p= 0.6034)	

Defined as an increase of ≥ 1.0 point from the baseline EDSS score for patients with baseline score of 5.5 or less, or ≥ 0.5 when the baseline score is > 5.5 , Kaplan-Meier estimates at Week 120

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Figure 2: Kaplan-Meier Plot of Time to Onset of Confirmed Disability Progression Sustained for at Least 12 Weeks with the Initial Event of Neurological Worsening Occurring during the Double-blind Treatment Period (ITT Population)*



* All patients in this analysis had a minimum of 120 weeks of follow-up. The primary analysis is based on all events accrued

Post-hoc analyses were performed in the Extended Controlled Period (ECP), which includes double-blinded treatment and approximately 9 additional months of controlled follow-up before continuing into the Open-Label Extension (OLE) or until withdrawal from study treatment. The proportion of patients with 24 week Confirmed Disability Progression of EDSS \geq 7.0 (24W-CDP of EDSS \geq 7.0, time to wheelchair) was 9.1% in the placebo group compared to 4.8% in the Ocrevus group at Week 144, resulting in a 47% risk reduction of the time to wheelchair (HR 0.53, [0.31, 0.92]) during the ECP. These results were exploratory in nature and included data after unblinding.

5.2.2 Immunogenicity

Patients in MS trials (WA21092, WA21093 and WA25046) were tested at multiple time points (baseline and every 6 months post treatment for the duration of the trial) for anti- drug antibodies (ADAs). Out of 1311 patients treated with Ocrelizumab, 12 (~1%) tested positive for treatment-emergent ADAs, of which 2 patients tested positive for neutralizing antibodies. The impact of treatment-emergent ADAs on safety and efficacy cannot be assessed given the low incidence of ADA associated with OCREVUS.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Immunogenicity data are highly dependent on the sensitivity and specificity of the test methods used. Additionally, the observed incidence of a positive result in a test method may be influenced by several factors, including sample handling, timing of sample collection, drug interference, concomitant medication and the underlying disease. Therefore, comparison of the incidence of antibodies to OCREVUS with the incidence of antibodies to other products may be misleading.

5.3 Pharmacokinetic properties

Pharmacokinetics of OCREVUS in the MS studies were described by a two compartment model with time-dependent clearance, and with PK parameters typical for an IgG1 monoclonal antibody. Clearance and central volume were estimated at 0.17 L/day and 2.78 L, peripheral volume and inter-compartment clearance at 2.68 L and 0.294 L/day, and initial time-dependent clearance at 0.0489 L/day which declined with a half-life of 33 weeks. The overall exposure (AUC over the 24 week dosing intervals) was identical in the 2 x 300 mg in PPMS and 1 x 600 mg in RMS studies, as expected given an identical dose was administered. Area under curve (AUC_τ) after the 4th dose of 600 mg OCREVUS was 3510 µg/mL•day, and mean maximum concentration (C_{max}) was 212 µg/mL in RMS (600 mg infusion) and 141 µg/mL in PPMS (300 mg infusions). Terminal half-life was 26 days.

5.3.1 Absorption

OCREVUS is administered as an IV infusion. There have been no studies performed with other routes of administration.

5.3.2 Distribution

The population pharmacokinetics estimate of the central volume of distribution was 2.78 L. Peripheral volume and inter-compartment clearance were estimated at 2.68 L and 0.294 L/day

5.3.3 Metabolism

The metabolism of OCREVUS has not been directly studied, as antibodies are cleared principally by catabolism.

5.3.4 Elimination

Constant clearance was estimated at 0.17 L/day, and initial time-dependent clearance at 0.0489 L/day, which declined with a half-life of 33 weeks. The terminal elimination half-life was 26 days.

5.3.5 Pharmacokinetics in Special Populations

Pediatric Population

No studies have been conducted to investigate the pharmacokinetics of OCREVUS in children and adolescents (<18 years of age).

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Geriatric Population

No studies have been conducted to investigate the pharmacokinetics of OCREVUS in patients ≥ 65 years.

Renal impairment

No formal pharmacokinetic study has been conducted. Patients with mild renal impairment were included in clinical trials and no change in the pharmacokinetics of OCREVUS was observed in those patients.

Hepatic impairment

No formal pharmacokinetic study has been conducted. Patients with mild hepatic impairment were included in clinical trials, and no change in the pharmacokinetics was observed in those patients.

6. NONCLINICAL PROPERTIES

6.1 Animal Toxicology or Pharmacology

6.1.1 Carcinogenicity

No carcinogenicity studies have been performed as no appropriate animal or *in vitro* models are available to assess the carcinogenic potential of OCREVUS.

6.1.2 Genotoxicity

No studies have been performed to assess the mutagenic potential of OCREVUS. As an antibody, OCREVUS is not expected to interact directly with DNA or other chromosomal material.

6.1.3 Impairment of Fertility

Nonclinical data reveal no special hazards for humans based on studies of male and female fertility in cynomolgus monkeys.

6.1.4 Reproductive Toxicity

It is not known whether OCREVUS can cause harm to the fetus when administered to pregnant women or whether it affects reproductive capacity. In an embryo-fetal developmental study in cynomolgus monkeys, there was no evidence of maternal toxicity, teratogenicity, or embryotoxicity following OCREVUS administration at 75/100 mg/kg (loading dose/study dose). As IgG molecules are known to cross the placental barrier OCREVUS causes depletion of B-cells in the fetuses of treated cynomolgus monkeys.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

In a pre- and post-natal development study in cynomolgus monkeys, administration of OCREVUS (15/20 and 75/100 mg/kg loading/study doses, which correspond to human equivalent doses of approximately 3000 mg (approximately 5 x clinical dose) and 15000 mg (approximately 25 x clinical dose), respectively) was associated with glomerulopathy (7/24 animals), lymphoid follicle formation in bone marrow (9/24 animals), and lymphoplasmacytic inflammation in the kidney (2/24 animals). Testicular weights of the neonates were significantly reduced in the 75/100 mg/kg group compared with controls. There were two cases of moribundity on study (2/24), one attributed to weakness due to premature birth accompanied by opportunistic infection and the other to an infective meningoencephalitis involving the cerebellum of the offspring from a maternal dam with an active infection (mastitis). The course of both neonatal infections could have potentially been impacted by B-cell depletion. Newborn offspring of maternal animals exposed to OCREVUS were noted to have depleted B-cell populations during the post-natal phase. Measurable levels of OCREVUS were detected in milk (approximated 0.2% of steady state trough serum levels) during the lactation period (see section 2.5.3 *Lactation*).

6.1.5 Other

Nonclinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, acute and repeated dose toxicity

7. DESCRIPTION

Ocrelizumab is a recombinant humanized monoclonal antibody directed against CD20-expressing B-cells.

Ocrelizumab is a glycosylated immunoglobulin G1 (IgG1) with a molecular mass of approximately 145 kDa.

ATC Code: L04AA36

8. PHARMACEUTICAL PARTICULARS

8.1 Incompatibilities

No incompatibilities between OCREVUS and polyvinyl chloride (PVC) or polyolefin (PO) bags and IV administration sets have been observed.

Do not use other diluents to dilute OCREVUS since its use has not been tested.

8.2 Shelf-life

24 Months.

This medicine should not be used after the expiry date (EXP) shown on the pack.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

The prepared infusion solution should be used immediately. If not used immediately, it can be stored up to 24 hours at 2 - 8°C and 8 hours at room temperature. In the event an IV infusion cannot be completed the same day, the remaining solution should be discarded.

8.3 Packaging information

OCREVUS (Ocrelizumab) injection is a preservative-free, sterile, clear or slightly opalescent, and colorless to pale brown solution supplied as a carton containing one 300 mg/10 mL (30 mg/mL) single-dose vial

8.4 Storage and handling instructions

Store vials at 2-8°C

Keep the vial in the outer carton to protect from light

Do not freeze. Do not shake.

OCREVUS should be prepared by a healthcare professional using aseptic technique. A sterile needle and syringe should be used to prepare the diluted infusion solution

The product contains no preservative and is intended for single use only.

OCREVUS may contain fine translucent and/or reflective particles associated with enhanced opalescence. Do not use the solution if discolored or if the solution contains discrete foreign particulate matter.

OCREVUS drug product must be diluted before administration. Solutions of OCREVUS for IV administration are prepared by dilution of the drug product into an infusion bag containing 0.9% sodium chloride (300 mg/250 mL or 600 mg/500 mL), to a final drug concentration of approximately 1.2 mg/mL.

The diluted infusion solution must be administered using an infusion set with a 0.2 or 0.22 micron in-line filter.

Prior to the start of the IV infusion, the content of the infusion bag should be at room temperature

Disposal of unused/expired medicines

The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided. Use established “collection systems”, if available in your location.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

The following points should be strictly adhered to regarding the use and disposal of syringes and other medicinal sharps:

- Needles and syringes should never be reused.
- Place all used needles and syringes into a sharps container (puncture-proof disposable container).

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

9. PATIENT COUNSELLING INFORMATION

Infusion Reactions

Inform patients about the signs and symptoms of infusion reactions, and that infusion reactions can occur up to 24 hours after infusion. Advise patients to contact their healthcare provider immediately for signs or symptoms of infusion reactions see section 4.4 *Special warnings and precautions for use*)

Infection

Advise patients to contact their healthcare provider for any signs of infection during treatment or after the last dose (see section 5 *Pharmacological Properties*). Signs include fever, chills, constant cough, or signs of herpes such as cold sore, shingles, or genital sores (see section 4.4 *Special warnings and precautions for use*)

Advise patients that PML has happened with drugs that are similar to OCREVUS and may happen with OCREVUS. Inform the patient that PML is characterized by a progression of deficits and usually leads to death or severe disability over weeks or months. Instruct the patient of the importance of contacting their doctor if they develop any symptoms suggestive of PML. Inform the patient that typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes (see section 4.4 *Special warnings and precautions for use*)

Advise patients that OCREVUS may cause reactivation of hepatitis B infection and that monitoring will be required if they are at risk (see section 4.4 *Special warnings and precautions for use*)

Advise patients that herpes infections, including serious herpes infections affecting the central nervous system, skin, and eyes, have occurred during treatment with OCREVUS. Advise patients to promptly contact their healthcare provider if they experience any signs or symptoms of herpes infections including oral or genital symptoms, fever, skin rash, pain, itching, decreased visual acuity, eye redness, eye pain, headache, neck stiffness, or change in mental status (see section 4.4 *Special warnings and precautions for use*)

Vaccination

Advise patients to complete any required live or live-attenuated vaccinations at least 4 weeks and, whenever possible, non-live vaccinations at least 2 weeks prior to initiation of OCREVUS. Administration of live-

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

attenuated or live vaccines is not recommended during OCREVUS treatment and until B-cell recovery (see section 4.4 *Special warnings and precautions for use*)

Malignancies

Advise patients that an increased risk of malignancy, including breast cancer, may exist with OCREVUS. Advise patients that they should follow standard breast cancer screening guidelines (see section 4.4 *Special warnings and precautions for use*)

Contraception

Females of childbearing potential should use effective contraception while receiving OCREVUS and for 6 months after the last infusion of OCREVUS (see section 5 Pharmacological Properties)

Pregnancy

Instruct patients that if they are pregnant or plan to become pregnant while taking OCREVUS they should inform their healthcare provider (see section 4.6 Use in Special Populations)

10. DETAILS OF MANUFACTURER

Manufactured by: F. Hoffmann-La Roche Ltd, Wurmisweg, 4303 Kaiseraugst, Switzerland

Imported and Marketed by:

Roche Products (India) Pvt. Ltd.,

C/O. Parekh Integrated Services Pvt. Ltd, Gala No. A1, First Floor, Warehouse no. 6, BGR Logistics Park, NH-3, Zone 5, Bhiwandi, Maharashtra (India) – 421302

11. DETAILS OF PERMISSION OR LICENCE NUMBER WITH DATE

IMP/BIO/23/000028 dated 20-Apr-2023

12. DATE OF REVISION

Current at August 2022, Version 1.0